Market Overview

Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects

Share:
Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects

Alkermes Plc (NASDAQ: ALKS) has enjoyed a relatively strong Street backing over the last six months despite its nearly 40-percent drop. On Wednesday, though, it caught a downgrade, bringing its ratings mix to six Buys, five Holds and two Sells, according to TipRanks.

The Rating

Goldman Sachs analyst Terence Flynn cut Alkermes from Neutral to Sell and lowered his price target from $49 to $26.

The Thesis

Flynn removed two key elements from its model: sales of ALKS-5461 for depression and the potential for merger activity.

“We expect FDA to issue a complete response letter (i.e., non-approval) on or before the Jan 31 PDUFA date and we don’t expect Study 217 to be sufficient to address potential FDA issues following the negative Adcom outcome (11/1),” he said of the depression candidate.

Additionally, channel checks suggest the schizophrenia treatment, ALKS-3831, posts unfavorable metabolic and weight-gain data and will not likely transform treatment.

“The level of SG&A investment ahead of a potential ‘3831 launch is underappreciated (we raise our expenses and are now 9%-15% higher than consensus in 2019-2021),” the analyst wrote in the note.

Flynn would take a more bullish stance on the stock if Alkermes could better differentiate the ALKS-3831 metabolic profile from Zyprexa; secure FDA approval of ALKS-5461; drive leverage in Vivitrol sales; outperform estimates for Aristada; or posts strong activity for ALKS-4230 in cancer treatment.

Price Action

At time of publication, Alkermes shares were down 3.4 percent at $30.72.

Related Links:

FDA Committees' Unfavorable Ruling Depresses Alkermes Shares

Alkermes Falls 20% After FDA Refusal To File Letter

Latest Ratings for ALKS

DateFirmActionFromTo
Sep 2019UpgradesUnderweightEqual-Weight
Jul 2019UpgradesSellNeutral
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Terence FlynnAnalyst Color Downgrades Price Target Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (ALKS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WEEDMKM PartnersMaintains30.0
NKTRH.C. WainwrightMaintains32.0
DISCARosenblattMaintains33.0
GOODNational SecuritiesInitiates Coverage On25.0
XOGCitiDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

10 Biggest Price Target Changes For Wednesday

Bloomin Brands Performance Will Be Supported By Outback, Morgan Stanley Says